World’s First Commercial iPSC Cell Plant Opens in Japan

March 26, 2018

(The Scientist) – A pharmaceutical company based in Osaka, Japan, opened a regenerative medicine center yesterday (March 22) that will produce cells derived from induced pluripotent stem (iPS) cells for commercial applications. The center is the first plant of its kind globally. It will initially produce cells for use in clinical trials.